Literature DB >> 6668067

The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.

S Srinivasan, E L Francke, C Ortiz-Neu, A S Prince, H C Neu.   

Abstract

Moxalactam was evaluated as the sole therapy of 45 episodes of infection in 41 patients due primarily to bacteria resistant to older antibiotics. Infections included bacteremias, pulmonary, skin and soft tissue infections, osteomyelitis, and meningitis. Clinical and bacteriological cure was achieved in 69% of infections. Cure was achieved with moxalactam in patients infected with cefazolin-resistant, carbenicillin-resistant, chloramphenicol and gentamicin-resistant organisms. Although adverse reactions were generally mild, diarrhea developed in five patients, a major increase in prothrombin time and bleeding in three patients and a disulfiram reaction in two patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6668067     DOI: 10.1007/bf01641349

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  25 in total

1.  A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli.

Authors:  M F Parry; H C Neu
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

2.  Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

Authors:  S Srinivasan; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime.

Authors:  K P Fu; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

5.  Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  E L Francke; H C Neu
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

6.  Susceptibility of moxalactam to beta-lactamase.

Authors:  M H Richmond
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

7.  Moxalactam in the therapy of serious infections.

Authors:  R L Marier; S Faro; C V Sanders; W Williams; F Derks; A Janney; K Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

8.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

10.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
View more
  1 in total

Review 1.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.